63 related articles for article (PubMed ID: 10871843)
1. Transcriptional modulation of the anti-apoptotic protein BCL-XL by the paired box transcription factors PAX3 and PAX3/FKHR.
Margue CM; Bernasconi M; Barr FG; Schäfer BW
Oncogene; 2000 Jun; 19(25):2921-9. PubMed ID: 10871843
[TBL] [Abstract][Full Text] [Related]
2. Regulation of expression of stromal-derived factor-1 receptors: CXCR4 and CXCR7 in human rhabdomyosarcomas.
Tarnowski M; Grymula K; Reca R; Jankowski K; Maksym R; Tarnowska J; Przybylski G; Barr FG; Kucia M; Ratajczak MZ
Mol Cancer Res; 2010 Jan; 8(1):1-14. PubMed ID: 20068066
[TBL] [Abstract][Full Text] [Related]
3. Tumor-specific PAX3-FKHR transcription factor, but not PAX3, activates the platelet-derived growth factor alpha receptor.
Epstein JA; Song B; Lakkis M; Wang C
Mol Cell Biol; 1998 Jul; 18(7):4118-30. PubMed ID: 9632796
[TBL] [Abstract][Full Text] [Related]
4. Identification of a new class of PAX3-FKHR target promoters: a role of the Pax3 paired box DNA binding domain.
Zhang L; Wang C
Oncogene; 2007 Mar; 26(11):1595-605. PubMed ID: 16964289
[TBL] [Abstract][Full Text] [Related]
5. The oncogenic potential of the Pax3-FKHR fusion protein requires the Pax3 homeodomain recognition helix but not the Pax3 paired-box DNA binding domain.
Lam PY; Sublett JE; Hollenbach AD; Roussel MF
Mol Cell Biol; 1999 Jan; 19(1):594-601. PubMed ID: 9858583
[TBL] [Abstract][Full Text] [Related]
6. The transcriptional activator PAX3-FKHR rescues the defects of Pax3 mutant mice but induces a myogenic gain-of-function phenotype with ligand-independent activation of Met signaling in vivo.
Relaix F; Polimeni M; Rocancourt D; Ponzetto C; Schäfer BW; Buckingham M
Genes Dev; 2003 Dec; 17(23):2950-65. PubMed ID: 14665670
[TBL] [Abstract][Full Text] [Related]
7. PLK1 phosphorylates PAX3-FOXO1, the inhibition of which triggers regression of alveolar Rhabdomyosarcoma.
Thalhammer V; Lopez-Garcia LA; Herrero-Martin D; Hecker R; Laubscher D; Gierisch ME; Wachtel M; Bode P; Nanni P; Blank B; Koscielniak E; Schäfer BW
Cancer Res; 2015 Jan; 75(1):98-110. PubMed ID: 25398439
[TBL] [Abstract][Full Text] [Related]
8. Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
Ahn EH; Mercado GE; Laé M; Ladanyi M
Oncol Rep; 2013 Aug; 30(2):968-78. PubMed ID: 23733015
[TBL] [Abstract][Full Text] [Related]
9. The PAX-FOXO1s trigger fast trans-differentiation of chick embryonic neural cells into alveolar rhabdomyosarcoma with tissue invasive properties limited by S phase entry inhibition.
Gonzalez Curto G; Der Vartanian A; Frarma YE; Manceau L; Baldi L; Prisco S; Elarouci N; Causeret F; Korenkov D; Rigolet M; Aurade F; De Reynies A; Contremoulins V; Relaix F; Faklaris O; Briscoe J; Gilardi-Hebenstreit P; Ribes V
PLoS Genet; 2020 Nov; 16(11):e1009164. PubMed ID: 33175861
[TBL] [Abstract][Full Text] [Related]
10. 17-Aminogeldanamycin Inhibits Constitutive Nuclear Factor-Kappa B (NF-κB) Activity in Patient-Derived Melanoma Cell Lines.
Hartman ML; Rogut M; Mielczarek-Lewandowska A; Wozniak M; Czyz M
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32466509
[TBL] [Abstract][Full Text] [Related]
11. Destined to Die: Apoptosis and Pediatric Cancers.
Choo Z; Loh AHP; Chen ZX
Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31652776
[TBL] [Abstract][Full Text] [Related]
12. The PAX3-FOXO1 oncogene alters exosome miRNA content and leads to paracrine effects mediated by exosomal miR-486.
Ghamloush F; Ghayad SE; Rammal G; Fahs A; Ayoub AJ; Merabi Z; Harajly M; Zalzali H; Saab R
Sci Rep; 2019 Oct; 9(1):14242. PubMed ID: 31578374
[TBL] [Abstract][Full Text] [Related]
13. Lineage Tracing Reveals a Subset of Reserve Muscle Stem Cells Capable of Clonal Expansion under Stress.
Scaramozza A; Park D; Kollu S; Beerman I; Sun X; Rossi DJ; Lin CP; Scadden DT; Crist C; Brack AS
Cell Stem Cell; 2019 Jun; 24(6):944-957.e5. PubMed ID: 31006621
[TBL] [Abstract][Full Text] [Related]
14. An Examination of the Role of Transcriptional and Posttranscriptional Regulation in Rhabdomyosarcoma.
Hron AJ; Asakura A
Stem Cells Int; 2017; 2017():2480375. PubMed ID: 28638414
[TBL] [Abstract][Full Text] [Related]
15. The importance of being dead: cell death mechanisms assessment in anti-sarcoma therapy.
Rello-Varona S; Herrero-Martín D; Lagares-Tena L; López-Alemany R; Mulet-Margalef N; Huertas-Martínez J; Garcia-Monclús S; García Del Muro X; Muñoz-Pinedo C; Tirado OM
Front Oncol; 2015; 5():82. PubMed ID: 25905041
[TBL] [Abstract][Full Text] [Related]
16. Melanoma biomolecules: independently identified but functionally intertwined.
Dye DE; Medic S; Ziman M; Coombe DR
Front Oncol; 2013 Sep; 3():252. PubMed ID: 24069584
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of impaired differentiation in rhabdomyosarcoma.
Keller C; Guttridge DC
FEBS J; 2013 Sep; 280(17):4323-34. PubMed ID: 23822136
[TBL] [Abstract][Full Text] [Related]
18. Obatoclax (GX15-070) triggers necroptosis by promoting the assembly of the necrosome on autophagosomal membranes.
Basit F; Cristofanon S; Fulda S
Cell Death Differ; 2013 Sep; 20(9):1161-73. PubMed ID: 23744296
[TBL] [Abstract][Full Text] [Related]
19. Survivin blockade sensitizes rhabdomyosarcoma cells for lysis by fetal acetylcholine receptor-redirected T cells.
Simon-Keller K; Paschen A; Hombach AA; Ströbel P; Coindre JM; Eichmüller SB; Vincent A; Gattenlöhner S; Hoppe F; Leuschner I; Stegmaier S; Koscielniak E; Leverkus M; Altieri DC; Abken H; Marx A
Am J Pathol; 2013 Jun; 182(6):2121-31. PubMed ID: 23562272
[TBL] [Abstract][Full Text] [Related]
20. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma.
Crose LE; Etheridge KT; Chen C; Belyea B; Talbot LJ; Bentley RC; Linardic CM
Clin Cancer Res; 2012 Jul; 18(14):3780-90. PubMed ID: 22648271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
